

---

Subject: zymo hair

Posted by [pippo24](#) on Mon, 20 Oct 2008 10:16:56 GMT

[View Forum Message](#) <> [Reply to Message](#)

---

Hey leute, hab grad so ein lab in Italien gefunden, welches enzymatische wirkstoffe gegen HA produziert.

[http://209.85.135.104/translate\\_c?hl=de&sl=pt&u=http://www.iralab.it/zymo.asp&prev=/search%3Fq%3Dhttp://www.iralab.it/zymo.asp%26hl%3Dde&usg=ALkJrhjOHAvxwKGD\\_ugo-S4\\_9gEh-F-I0Sg](http://209.85.135.104/translate_c?hl=de&sl=pt&u=http://www.iralab.it/zymo.asp&prev=/search%3Fq%3Dhttp://www.iralab.it/zymo.asp%26hl%3Dde&usg=ALkJrhjOHAvxwKGD_ugo-S4_9gEh-F-I0Sg)

Die Produkte die sie haben sind:

ZYMO Hydroxysteroid DHEYDROGENASE komplex

ZYMO Kher

ZYMO Khera S

schaut euch doch mal die dazugehörigen PDFs an.

Alkalische Phosphatase fand ich schon immer cool

---

---

Subject: Re: zymo hair

Posted by [pilos](#) on Mon, 20 Oct 2008 10:29:58 GMT

[View Forum Message](#) <> [Reply to Message](#)

---

alles schön rechnerei.....

nix in vivo....

---

---

Subject: Re: zymo hair

Posted by [pippo24](#) on Mon, 20 Oct 2008 10:37:12 GMT

[View Forum Message](#) <> [Reply to Message](#)

---

Zitat:nix in vivo....

doch die haben auch in vivo:Aber nur zu dem ZYMO HYDROXYSTEROID DHEYDROGENASE COMPLEX

Study Design

---

This was a double blind study in which the 30 volunteers were randomly distributed into two groups, each one of 15 subjects, treated with the active formulation (treatment A) or placebo (treatment B). Treatment was twice daily (morning/evening) for 6 months.

#### Assessment Method

The evaluation has been made by counting the hair number and measuring hair length in a selected area of the scalp of 25 cm<sup>2</sup>. The same area was also observed for the general aspect and possible irritative reactions. The area was delimited by four points indelibly marked with Dansil chloride (1-dimethylaminonaphtalene-5-sulphonyl

between 50 and 100. On this area hairs were cut at a length of 3.5 mm by an electric shaver passed through a squared mask 3.5 mm high leant over the delimited surface. The evaluation was performed before the first treatment and at 15 days intervals along the entire study period, everytime repositioning the mask over the selected area.

#### Product administration

The active formulation and placebo (25 mg) were contained in a sealed capsule combined with a 10 ml vial containing distilled water to be used at each application. The powder was dissolved in the vial at the moment of application, which was every morning and evening. The application was preceded by careful washing of the scalp with water at about 45°C and drying, by means of a towel, of excess water; the solution 14213ZymoHSOR doen.doc 17

(10 ml) was then distributed over the entire scalp surface and rubbed until complete absorption of the product.

#### RESULTS AND CONCLUSIONS

Mean values of hair number and hair length observed during treatment with the active formulation (treatment A) and placebo (treatment B) are depicted in the graphs below Fig. 1 and 2).

As can be seen, treatment with the active formulation, containing the enzyme hydroxysteroid dhydrogenase, showed a good efficacy in hair growth. In fact, in this case, the mean value of length after the 6 month treatment was 8.2 mm, whereas it was 6.1 mm with the placebo treatment. These values are intended as difference between the mean length observed at the end of treatment period and the initial value of 3.5 mm. Observing the hair number, the mean value was almost unchanged or a little bit reduced with the placebo (from 91 to 86), while it raised of 73%, from 84 to 145, with the formulation containing the enzyme.

These results clearly demonstrate that the enzyme hydroxysteroid dhydrogenase is able to reduce the amount of dihydrotestosterone which is responsible of the androgenetic alopecia. Its total or partial removal in an acceptable time revitalizes the hair bulb allowing hair regrowth. Of course, the efficacy is appreciable in subjects affected by androgenetic alopecia when the degree of severity is such that a recovery is still possible, that is to say that baldness is at its onset or at a moderate degree of severity. In fact, in our trial it was chosen an area with a reduced number of hair instead of a complete baldness. On the other hand, since the rationale for use is the reduction of the excessive presence of DHT, it can be assume that the product is not effective in heathy subjects where DHT is absent or present at a minimum amount

Finally, any irritative reaction appeared during the entire treatment period, either with the active formulation or placebo, demonstrating the safety of the product.